Compare ELOG & RGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELOG | RGNT |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | China | Israel |
| Employees | N/A | 8 |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 11.1M |
| IPO Year | N/A | N/A |
| Metric | ELOG | RGNT |
|---|---|---|
| Price | $1.22 | $1.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.8K | ★ 24.5K |
| Earning Date | 07-17-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $1.54 |
| 52 Week High | $3.07 | $8.35 |
| Indicator | ELOG | RGNT |
|---|---|---|
| Relative Strength Index (RSI) | 67.35 | 25.56 |
| Support Level | $0.84 | N/A |
| Resistance Level | $1.36 | $3.35 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 69.64 | 1.56 |
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products. Its segments are Transportation services and Warehouse subleasing services. The group generates the majority of its revenue from Transportation services.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.